

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age and older

Diagnoses

Patient must have **ONE** of the following:

1. Newly diagnosed acute myeloid leukemia (AML)
 - a. FLT3 mutation-positive AML detected by FDA-approved test
 - b. Concurrent standard induction therapy with cytarabine and daunorubicin and cytarabine consolidation
2. Aggressive systemic mastocytosis (ASM)
3. Systemic mastocytosis with associated hematological neoplasm (SM-AHN)
4. Mast cell leukemia (MCL)

Prior - Approval Limits

Quantity	25 mg	672 capsules per 84 days
Duration	12 months	

Prior – Approval *Renewal* Requirements

Age 18 years of age and older

Diagnoses

Patient must have **ONE** of the following:

1. Acute myeloid leukemia (AML)
2. Aggressive systemic mastocytosis (ASM)
3. Systemic mastocytosis with associated hematological neoplasm (SM-AHN)
4. Mast cell leukemia (MCL)

AND the following:



**BlueCross
BlueShield**

Federal Employee Program.

**RYDAPT
(midostaurin)**

- a. NO disease progression or unacceptable toxicity

Prior - Approval *Renewal* Limits

Same as above